(Q42646812)

4 November 2017

title

Long-acting risperidone improves negative symptoms in stable psychotic patients (English)

1 reference

4 November 2017

1 reference

1 reference

V A Curtis

1

1 reference

4 November 2017

K Katsafouros

2

1 reference

4 November 2017

H-J Möller

3

1 reference

4 November 2017

R Medori

4

1 reference

4 November 2017

E Sacchetti

5

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

Journal of Psychopharmacology

4 November 2017

published in

1 reference

4 November 2017

volume

22

1 reference

4 November 2017

issue

3

1 reference

4 November 2017

page(s)

254-261

1 reference

Manual for the Extrapyramidal Symptom Rating Scale (ESRS).

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Clinical profile of an atypical antipsychotic: risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Treatment of schizophrenia negative symptoms: future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

The influence of neurocognitive deficits and symptoms on disability in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Drug treatment of the negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

The NIMH-MATRICS consensus statement on negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

21 January 2018

Risperidone: a review

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Amisulpride: Is There a Treatment for Negative Symptoms in Schizophrenia Patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Quetiapine has a direct effect on the negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082119

21 January 2018

Identifiers

DOI

10.1177/0269881107082119

1 reference

4 November 2017

1 reference